BerandaIMGN • BMV
add
ImmunoGen Ord Shs
Tutup sebelumnya
$268,50
Rentang tahun
$268,50 - $268,50
Kapitalisasi pasar
8,72Â M USD
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2023info | Perubahan Y/Y |
---|---|---|
Pendapatan | 113,42Â jt | 637,72% |
Biaya operasional | 37,74Â jt | 12,26% |
Laba bersih | 30,75Â jt | 139,54% |
Margin laba bersih | 27,11 | 105,36% |
Penghasilan per saham | 0,10 | 132,26% |
EBITDA | 26,38Â jt | 134,26% |
Tarif pajak efektif | -3,94% | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2023info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 605,54Â jt | 95,64% |
Total aset | 822,10Â jt | 129,13% |
Total liabilitas | 260,50Â jt | 44,09% |
Total ekuitas | 561,60 jt | — |
Saham yang beredar | 266,26 jt | — |
Harga terhadap reservasi | 127,25 | — |
Tingkat pengembalian aset | 8,45% | — |
Pengembalian modal | 10,17% | — |
Arus Kas
Perubahan bersih tunai
(USD) | Sep 2023info | Perubahan Y/Y |
---|---|---|
Laba bersih | 30,75Â jt | 139,54% |
Kas dari operasi | 2,77Â jt | 104,31% |
Tunai dari investasi | -1,35Â jt | -124,92% |
Tunai dari pembiayaan | 32,13Â jt | 7.056,35% |
Perubahan bersih tunai | 33,55Â jt | 152,12% |
Arus kas bebas | -2,32Â jt | 91,72% |
Tentang
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
Didirikan
1981
Kantor pusat
Situs
Karyawan
277